Distinct Elevation of Levels of Anti-Caenorhabditis elegans Antibody in Sera of Patients with Inflammatory Bowel Disease
AUTOR(ES)
Oshitani, Nobuhide
FONTE
American Society for Microbiology
RESUMO
Dysregulation of immune responses to intestinal exogenous antigens contributes to the pathogenesis of inflammatory bowel disease, but the specific antigen responsible for the pathogenesis of inflammatory bowel disease is unknown. We measured serum antibody titers against Caenorhabditis elegans antigens. Immunoglobulin G (IgG) and IgG subclass anti-C. elegans antibodies in serum samples from 29 patients with ulcerative colitis, 30 patients with Crohn's disease, 7 patients with intestinal Behçet's disease, and 11 healthy controls were measured by enzyme-linked immunosorbent assay. Serum IgG and IgG2 antibody titers against C. elegans were significantly higher in patients with inflammatory bowel disease than in controls. Antibody levels were not affected by age, gender, disease activity, extent of disease, or small bowel involvement. The anti-C. elegans antibody titer was significantly lower in patients with Crohn's disease taking mesalazine or sulfasalazine than in patients not taking these drugs. The increased immune responses to C. elegans found in patients with inflammatory bowel disease reflect dysregulated immune responses to enteric antigens, which might play a role in the pathogenesis of inflammatory bowel disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=193898Documentos Relacionados
- IMMUNIZATION STATUS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
- Reduced bone density in patients with inflammatory bowel disease.
- MYO9B polymorphisms in patients with inflammatory bowel disease
- In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
- Postoperative mortality in inflammatory bowel disease patients
